The Trump administration has bought up virtually all stocks for the next three months of a drug shown to work against Covid-19.

The US Department of Health and Human Services (HSS) said it had secured more than 500,000 treatment courses of remdesivir for American hospitals.

This represents 100% of the US pharmaceutical firm Gilead’s projected production for July (94,200 treatment courses), 90% of production in August (174,900 treatment courses), and 90% of production in September (232,800 treatment courses), alongside an allocation for clinical trials.

Remdesivir is an anti-viral drug that was developed for use against Ebola.

It has been approved for use in Covid-19 patients by the US and the UK, among other countries, after data suggested it can cut recovery time by about four days.

However, there is no clinical trial data as yet to suggest it improves survival from coronavirus.

This site uses Akismet to reduce spam. Learn how your comment data is processed.